ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Kazia Therapeutics Ltd

Kazia Therapeutics Ltd (KZIA)

0.3442
0.0532
(18.28%)
Closed April 17 4:00PM
0.3594
0.0152
(4.42%)
After Hours: 6:18PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.3594
Bid
0.3306
Ask
0.3596
Volume
322,624
0.2873 Day's Range 0.3887
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.291
Open
0.299
Last Trade
10
@
0.3596
Last Trade Time
Financial Volume
$ 106,777
VWAP
0.330964
Average Volume (3m)
-
Shares Outstanding
228,029,000
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Kazia Therapeutics Ltd

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Sydney, New South Wales, Aus
Founded
1970
Kazia Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KZIA. The last closing price for Kazia Therapeutics was $0.29. Over the last year, Kazia Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Kazia Therapeutics currently has 228,029,000 shares outstanding.

KZIA Latest News

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases PR Newswire SYDNEY, March 21, 2024 SYDNEY, March 21, 2024 /PRNewswire/ -- Kazia...

Kazia announces presentation of new data at AACR Annual Meeting

Kazia announces presentation of new data at AACR Annual Meeting PR Newswire SYDNEY, March 13, 2024 SYDNEY, March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a...

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint PR Newswire SYDNEY, Feb. 21, 2024 Paxalisib plus Radiotherapy Data Shows Promise for Treating...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INVOINVO BioScience Inc
$ 1.78
(134.21%)
226.64M
SINTSiNtx Technologies Inc
$ 0.0371
(62.01%)
490.26M
WISAWiSA Technologies Inc
$ 9.1941
(50.72%)
67.74M
EDBLEdible Garden AG Inc
$ 6.745
(48.24%)
12.9M
GCTKGlucoTrack Inc
$ 0.715
(36.27%)
654.24k
IZMICZOOM Group Inc
$ 6.01
(-88.22%)
14.54M
SBFMSunshine Biopharma Inc
$ 3.82
(-43.82%)
4.71M
DAREDare Bioscience Inc
$ 0.285455
(-41.13%)
4.26M
LGVNLongeveron Inc
$ 2.09
(-40.79%)
3.38M
ZAPPZapp Electric Vehicles Group Ltd
$ 0.1651
(-33.45%)
590.45k
SINTSiNtx Technologies Inc
$ 0.0371
(62.01%)
490.26M
INVOINVO BioScience Inc
$ 1.78
(134.21%)
226.64M
SQQQProShares UltraPro Short QQQ
$ 11.86
(3.67%)
168.86M
JAGXJaguar Health Inc
$ 0.163
(-8.58%)
133.95M
TQQQProShares UltraPro QQQ
$ 53.71
(-3.71%)
85.51M

KZIA Discussion

View Posts
powerbattles powerbattles 1 week ago
.40 breakout that is sweet $$
πŸ‘οΈ0
powerbattles powerbattles 2 weeks ago
Slowly win the race $$$
πŸ‘οΈ0
0210 0210 2 months ago
Profit is a pro-fit for winners! Expect bounce back, sooner than later.... GB & GL, Cuppy...and please do NOT worry unnecessarily.... Patience, grass-hopper. 20s are yummy.😋
πŸ‘οΈ0
Cuppy Cuppy 2 months ago
Why is this selling off?
πŸ‘οΈ0
Awl416 Awl416 2 months ago
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
πŸ‘οΈ0
trendzone trendzone 1 year ago
Another one,Mr big shot, average price $1.05 sold at $0.98 ohhhh so painful of a loss Mr bashbag,gee what happen Mr know it all with that pump and dump $FRGT at the time $0.85, about to go over a buck, now at $0.37, how's that working out for you,still holding that heavy bag, lol.
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 year ago
u sound angry....nice pick...lol
🖕🏻 1 🤡 1
trendzone trendzone 1 year ago
What they really need to do is get their heads out of their toxic azzes.
πŸ‘οΈ0
Pt3 Pt3 1 year ago
I'm in let. Goo positive
πŸ‘οΈ0
crudeoil24 crudeoil24 1 year ago
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
7:00 am ET October 27, 2022 (PR Newswire) Print
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT.

https://mma.prnewswire.com/media/1872892/Kazia_Logo.jpg

A poster presentation by Dr Gennie Parkman and colleagues, working in the laboratory of Professor Sheri Holmen, has shown paxalisib to be active in vitro and in vivo against a range of preclinical models of metastatic melanoma, the most aggressive form of skin cancer. Dr Parkman's data suggested substantial activity for paxalisib as monotherapy, and greater activity in combination with MEK and BRAF inhibitors, two classes of drugs that are commonly used for a substantial proportion of melanoma patients.

"This is among the most promising single agent data that we have seen in our research," commented Professor Sheri Holmen, lead investigator on the project. "Despite the widespread adoption of immunotherapy in recent years, there remains substantial unmet need in melanoma, particularly in those patients who develop brain metastases. We look forward to exploring the potential of paxalisib further in our research, and hopefully seeing the drug transition to a clinical trial in the near future."
πŸ‘οΈ0
Xrouter Xrouter 2 years ago
They really need management like Dr. Kelly to come back and fix it before it goes lower
πŸ‘οΈ0
Cuppy Cuppy 2 years ago
What's the consensus on this one now? I have been watching for a couple years now (no position). It seems dirt cheap IF it still has a chance for approvals.
πŸ‘οΈ0
Roadtojourney Roadtojourney 2 years ago
Wow dump on news?? Makes no sense.
πŸ‘οΈ0
doogdilinger doogdilinger 2 years ago
Yessir brotha you're on FIRE>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$
πŸ‘οΈ0
subslover subslover 2 years ago
Did you see that plow up for $3.37? Like a runaway spacecraft. :)
πŸ‘οΈ0
doogdilinger doogdilinger 2 years ago
KABOOM;)
πŸ‘οΈ0
subslover subslover 2 years ago
Interim data from the first stage of the study reports that all 9 evaluable patients experienced complete or partial response, representing an overall response rate (ORR) of 100%. For comparison, a typical ORR associated with whole brain radiotherapy alone can commonly range from 20-45% in published studies, of which some representative examples are indicated below.

The data has been accepted for an oral presentation at the upcoming 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, jointly organised by the Society for Neuro-Oncology (SNO) and the American Society for Clinical Oncology (ASCO), and held in Toronto, Canada from 12-13 August 2022.

Key Points

Approximately 200,000 cancer patients develop brain metastases in the United States each year. Brain metastases are typically very challenging to treat and are associated with poor prognosis. Radiotherapy remains a mainstay of clinical management.

Dr. Jonathan Yang, Director, Metastatic Disease, Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center is the Principal Investigator of this clinical trial that is examining the combination of paxalisib with whole brain radiotherapy for patients with brain metastases (NCT04192981). The trial is designed in two stages: an initial exploratory stage and a confirmatory expansion stage.

9 of 12 patients in the initial stage were evaluable for efficacy. All 9 patients exhibited complete or partial response, according to RANO-BM criteria, representing an ORR of 100%.

The patients comprised a range of primary tumours, with breast cancer the most common, representing one third of patients.

The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials, and a maximum tolerated dose (MTD) of 45mg daily in combination with radiotherapy was confirmed.

Recruitment to the expansion stage has already commenced, with the objective of recruiting an additional 12 patients.
Kazia CEO, Dr. James Garner, commented, "We are encouraged by this data and by the potential benefit it may indicate to this substantial and high-need group of patients. Radiotherapy is a ubiquitous component of the treatment paradigm for brain metastases, but resistance is common. Dr. Yang's study has shown a very promising signal that paxalisib may help to potentiate the effect of radiotherapy. We also learned recently that the ongoing Alliance study in brain metastases had graduated to an expansion stage in the breast cancer cohort, so this now represents the second positive signal for paxalisib in brain metastases, which we increasingly believe represents a very promising opportunity for the product candidate."

Brain Metastases

It is estimated that as many as 20% of all patients with cancer will develop brain metastases (secondary tumours in the central nervous system). The most common primary tumours that spread to the brain include lung, breast, colorectal, melanoma, and renal cell carcinoma. Median overall survival for patients diagnosed with brain metastases ranges from 2.3 to 7.7 months.[1] It is estimated that approximately 200,000 patients are diagnosed with brain metastases each year in the United States alone.[2]

Radiotherapy is the mainstay of treatment for brain metastases, and generally consists in either stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) or some combination thereof. The efficacy of WBRT differs according to the type of tumour and the number and volume of brain metastases, but several recent publications cite overall response rates of 20-45%.



Publication

Setting

ORR

Arrietta et al. (2020)

NSCLC

47.1 %

Zhou et al. (2021)

NSCLC (meta-analysis)

20.4% - 27.4%

Kim et al. (2020)

HER2+ breast cancer

42 %



Clinical Study Rationale and Design

Research by Dr. Yang and others has shown that activation of the PI3K pathway is common in brain metastases, even in some cases where it is not present in the primary tumour. Moreover, PI3K pathway activation appears to be induced by radiotherapy, and to confer upon the tumour resistance to radiotherapy. These observations provide a strong rationale for testing the combination of a brain-penetrant PI3K inhibitor with radiotherapy.

This phase I study is a single-arm prospective trial comprising patients with brain metastases or leptomeningeal metastases from any primary tumour. The primary objective is safety and tolerability. All patients have PI3K pathway mutations at baseline. The first stage of the study is intended to establish the MTD of paxalisib in combination with WBRT and to characterise safety and tolerability. The second stage is intended to elicit confirmatory signals of efficacy, with the intent to recruit a further 12 patients.

Next Steps

Enrolment to the second stage of the study is already underway and we currently estimate preliminary data from the second part of the phase I clinical trial in CY2023.

Kazia expects to discuss emerging data from this study, along with other research in brain metastases, with its scientific advisors and regulatory consultants in due course, with potential FDA consultation at a future date.

Summary of Abstract

Session 2: Multimodality Approaches to Primary and Secondary Brain Tumors - Invited
Speakers and Oral Abstracts
Friday, 12 August 2022
11am – 1pm

Abstract MMAP-05 - Phase I study of concurrent paxalisib and radiation therapy in patients with solid tumor brain metastases or leptomeningeal metastases harboring PI3K pathway mutations: results from the dose-escalation cohort (NCT04192981)
Lead Author: T Jonathan Yang, MD, PhD
Institution: Memorial Sloan Kettering Cancer Center, New York, NY

For More Information, Please Contact:-

In the United States:

Joe Green

Edison Investor Relations

jgreen@edisongroup.com

Phone: +1 646-653-7030

In Australia:

Jane Lowe

IR Department

jane.lowe@irdepartment.com.au

Phone: +61 411 117 774



About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for AT/RT in June 2022.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.

For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "intend," "potential," "prospective," or other similar words, and may include statements regarding the therapeutic potential of Kazia's product candidates and anticipated results from clinical trials. Kazia's product candidates may include paxalisib, EVT801, or other molecules, administered alone or in combination with other therapies for any disease. Any statement describing Kazia's future plans, strategies, intentions,
πŸ‘οΈ0
subslover subslover 2 years ago
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy
Jul. 06, 2022 6:44 AM ETKazia Therapeutics Limited (KZIA)By: Dulan Lokuwithana, SA News Editor1 Comment
https://seekingalpha.com/news/3854493-kzia-stock-gains-on-fdas-rare-pediatric-designation-for-cancer-therapy
πŸ‘οΈ0
Pt3 Pt3 2 years ago
My ask 10 where
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
WOOHOOOOOO
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
KZIA$
πŸ‘οΈ0
Cuppy Cuppy 2 years ago
Absolutely!
πŸ‘οΈ0
aussiekevin aussiekevin 3 years ago
Bad timing. Looks like an easy 10 bagger from here.
πŸ‘οΈ0
ipo_dude ipo_dude 3 years ago
Patience is king. Im Out!!! Glad i held on and didn’t sell @ loss.
πŸ‘οΈ0
aussiekevin aussiekevin 3 years ago
Yes, the news was very negative so this is not surprising.
πŸ‘οΈ0
ipo_dude ipo_dude 3 years ago
This is getting crushed
πŸ‘οΈ0
whatarush12 whatarush12 3 years ago
congrats!
πŸ‘οΈ0
ipo_dude ipo_dude 3 years ago
Do it??
πŸ‘οΈ0
Oger Oger 3 years ago
Check back with me Friday morning and ask me how I’m doing....
πŸ‘οΈ0
whatarush12 whatarush12 3 years ago
How's it going? I'd SELL this turd!!! OUCH! Losing more and more $$$

https://www.otcmarkets.com/stock/KZIA/financials

πŸ‘οΈ0
Oger Oger 3 years ago
Opens $12 or more on Monday...
πŸ‘οΈ0
Cuppy Cuppy 4 years ago
FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

9:14 pm ET August 23, 2020
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.

Key Points

Orphan Drug Designation (ODD) is a special status accorded to drugs which are considered promising potential treatments for rare ('orphan') diseases, generally defined as those which affect less than 200,000 cases per annum in the United States
ODD can provide drug developers with up to seven years of Orphan Drug Exclusivity (ODE), extending the effective life of a commercial product. It also provides opportunities for grant funding, protocol assistance, and financial benefits, such as a waiver of New Drug Application fees, and tax credits
Receipt of ODD follows award of Rare Pediatric Disease Designation (RPDD) for DIPG on 7 August 2020
Kazia CEO, Dr James Garner, commented, "Taken together, RPDD and ODD provide a powerful suite of incentives, opportunities, and protections for the development of paxalisib in DIPG. We look forward to seeing initial data from the ongoing phase I study in DIPG at St Jude Children's Research Hospital during the second half of calendar 2020. In parallel, we are working closely with collaborators, advisors, and researchers to determine the best path forward for paxalisib in this devastating disease."

He added, "This award of ODD concludes a program of regulatory optimisation that Kazia has initiated for paxalisib over the past six months. As we orient paxalisib towards commercialization, these special designations from FDA will allow us to move forward in the swiftest and most effective way possible."
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $KZIA Video Chart 08-20-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Nfixus Nfixus 4 years ago
The next year has a lot in the pipeline since FDA awards FTD today.
https://pennystocks.news/kazia-jumps-after-lead-drug-is-awarded-by-the-fda-kzia/
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $KZIA Video Chart 08-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $KZIA Video Chart 11-25-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
sanderburwil sanderburwil 4 years ago
KZIA Data PFS 8.4 months vs Temozolomide, Temodar (US) the only FDA approved drug to 5.3 months. Results are spectacular
πŸ‘οΈ0
sanderburwil sanderburwil 4 years ago
?$KZIA Kazia Therapeutics press release. Positive interim efficiency data from GDC-0084 Phase II Study in Glioblastoma released from SNO Conference. PFS) calculated at 8.4 months vs 5.3 Temozolomide?
πŸ‘οΈ0
sanderburwil sanderburwil 4 years ago
Kazia Therapeutics- $KZIA - Data-2019 SNO Conference OUT PFS 8.4 Months!!!!Expecting a $KRTX like move.
Temozolomide, Temodar (US) is the only FDA approved drug which extends patient lives from 4.4 months to 5.3 months. Kazia 8.4 is a huge success

We’re talking multi billion dollar market space here !!


CEO link on recent webcast suggest successful data here and co should be valued between 200-$500 million at this point of data is positive
Conservatively this is $45-$60 company given its potential and how easy and quick this will be FDA approved. They’re funded and they expect a β€œLARGER PHARMA” to bring GDC-0084 to fruition.


Dana Farber - Harvard Medical - MD Anderson - UCLA - Stephenson Cancer - John Theurer - Genetech

Poster Presenting Author(s)

Patrick Wen
Director, Center For Neuro-Oncology

ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status


πŸ‘οΈ0
sanderburwil sanderburwil 4 years ago
Kazia Therapeutics- $KZIA - Data presented this weekend -2019 SNO Conference . Halt lifted Monday morning. Expecting a $KRTX like move. CEO link on recent webcast suggest successful data here and co should be valued between 200-$500 million at this point of data is positive
Conservatively this is $45-$60 company given its potential and how easy and quick this will be FDA approved. They’re funded and they expect a β€œLARGER PHARMA” to bring GDC-0084 to fruition.


For GDC 0084 to work this well as a monotherapy it will CERTAINLY raise eyebrows of the worlds best experts over the weekend. Look who is presenting the data non other than Prof Wen!!!!




Dana Farber - Harvard Medical - MD Anderson - UCLA - Stephenson Cancer - John Theurer - Genetech

Poster Presenting Author(s)

Patrick Wen
Director, Center For Neuro-Oncology

ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status


πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock